New York state opens antitrust probe of Mylan's EpiPen

September 6, 2016

New York state has launched an antitrust probe into Mylan's sale of the EpiPen anti-allergy injector to local school systems, New York's attorney general announced Tuesday.

A preliminary review by the New York office concluded that Mylan may have inserted anticompetitive terms into EpiPen sales contracts with local school systems, said Attorney General Eric Schneiderman.

"No child's life should be put at risk because a parent, school, or healthcare provider cannot afford a simple, life-saving device because of a drug-maker's anti-competitive practices," Schneiderman said.

The probe comes as Mylan faces criticism from Democratic presidential candidate Hillary Clinton, among others, after instituting a five-fold increase in the price of the life-saving epinephrine injectors over a decade.

A Mylan spokeswoman said the drugmaker's "EpiPen4Schools" program has provided more than 700,000 free auto-injectors to more than 65,000 schools in the US and that the program "continues to adhere to all applicable laws and regulations."

The drugmaker previously offered to sell schools additional injectors beyond those provided for free under the program, but that "such restriction no longer remains," the Mylan spokeswoman said.

Since coming under fire for higher prices last month, Mylan has announced plans to offer a generic version of EpiPen and to expand patient assistance programs.

Democratic Senator Amy Klobuchar, whose daughter relies on EpiPen, has called on the Federal Trade Commission to launch an anti-trust investigation against the company, which has a near-monopoly in the market.

Mylan shares rose 0.8 percent to $40.29 in afternoon trade.

Explore further: Price rise for anti-allergy EpiPen sparks furor

Related Stories

Price rise for anti-allergy EpiPen sparks furor

August 23, 2016
A five-fold price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering.

Top US medical group blasts EpiPen's 'exorbitant' costs

August 24, 2016
The American Medical Association urged the maker of the EpiPen, a life-saving device that counteracts severe allergies, to drop its price Wednesday as public outrage mounted over a soaring cost hike.

Mylan boosts EpiPen patient programs, doesn't budge on price

August 25, 2016
Mylan is bulking up programs that help patients pay for its EpiPen emergency allergy treatment after weathering heated criticism about an average cost that has soared over the past decade.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

Pediatric allergist discusses EpiPen controversy

August 26, 2016
Members of Congress are calling for an investigation into the EpiPen maker Mylan. The pharmaceutical company has increased the price of EpiPens, from about $100 in 2008 to more than $500 today.

Clinton offers plan to prevent 'excessive' drug price hikes

September 2, 2016
Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.

Recommended for you

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

Introduction is different, but top medications for opioid addiction equally effective

November 14, 2017
With opioid addiction officially declared a public health emergency in the U.S., medical intervention to treat the illness is increasingly important in responding to the epidemic. Now, a new study concludes that two of the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.